MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-29-2026
Pro-Dex Total Assets 2011-2026 | PDEX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Pro-Dex
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.2 M | 52.5 M | 51.8 M | 51.9 M | 43.3 M | 39.1 M | 25.5 M | 19.9 M | 16.4 M | 11.1 M | 12.5 M | 11.7 M | 10.6 M | 12.8 M | 15.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 61.2 M | 10.6 M | 29.1 M |
Quarterly Total Assets Pro-Dex
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.3 M | 61.2 M | 64.3 M | 60.4 M | 54.3 M | 52.5 M | 50.5 M | 51.4 M | 49.6 M | 51.8 M | 47 M | 47.6 M | 48 M | 47.3 M | 43.9 M | 42.1 M | 41.9 M | 40.3 M | 40.3 M | 38.4 M | 30.8 M | 31.1 M | 31.1 M | 28.7 M | 28 M | 25.5 M | 25.5 M | 24 M | 25.2 M | 19.9 M | 19.9 M | 18.8 M | 18.2 M | 16.4 M | 16.4 M | 15 M | 11.9 M | 11.1 M | 11.1 M | 12.2 M | 12.3 M | 12.5 M | 12.5 M | 11.9 M | 11.5 M | 11.7 M | 11.7 M | 10.4 M | 10.5 M | 10.6 M | 10.6 M | 11.3 M | 12.6 M | 12.8 M | 12.8 M | 15.3 M | 15.3 M | 15.6 M | 15.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64.3 M | 10.4 M | 28 M |
Total Assets of other stocks in the Medical instruments industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
261 K | - | - | $ 810 M |  USA |
 |
iRhythm Technologies
IRTC
|
1.02 B | $ 127.76 | 4.42 % | $ 4.09 B | USA |
 |
Repro Med Systems
KRMD
|
28.2 M | $ 4.07 | 2.65 % | $ 188 M | USA |
 |
Microbot Medical
MBOT
|
81.5 M | $ 2.17 | -1.14 % | $ 99.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
7.81 M | $ 0.32 | 0.37 % | $ 26.3 M | USA |
 |
Luminex Corporation
LMNX
|
825 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
10.9 M | - | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
31.6 B | $ 76.16 | 0.47 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
20.1 M | $ 11.1 | -0.72 % | $ 26.9 M | USA |
 |
STERIS plc
STE
|
10.1 B | $ 222.32 | 0.23 % | $ 21.9 B | USA |
 |
The Cooper Companies
COO
|
12.4 B | $ 65.0 | 0.9 % | $ 12.9 B | USA |
 |
Teleflex Incorporated
TFX
|
6.95 B | $ 136.23 | -0.24 % | $ 6.08 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
213 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
2.07 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
192 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
4.67 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
4.46 B | - | -0.02 % | $ 16.3 B | USA |
 |
Utah Medical Products
UTMD
|
123 M | $ 67.76 | 0.87 % | $ 220 M | USA |
 |
Haemonetics Corporation
HAE
|
2.45 B | $ 61.27 | 2.24 % | $ 3.08 B | USA |
 |
electroCore
ECOR
|
18.7 M | $ 6.17 | -0.08 % | $ 52.3 K | USA |
 |
ICU Medical
ICUI
|
4.05 B | $ 123.83 | -0.79 % | $ 3.05 B | USA |
 |
Envista Holdings Corporation
NVST
|
5.68 B | $ 26.83 | 0.13 % | $ 4.51 B | USA |
 |
Isoray
ISR
|
267 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
20.5 B | $ 476.76 | -1.13 % | $ 170 B | USA |
 |
West Pharmaceutical Services
WST
|
4.27 B | $ 302.65 | -1.06 % | $ 21.9 B | USA |
 |
Glaukos Corporation
GKOS
|
940 M | $ 122.71 | 1.01 % | $ 5.94 B | USA |
 |
Masimo Corporation
MASI
|
2.63 B | $ 178.63 | - | $ 9.52 B | USA |
 |
InfuSystem Holdings
INFU
|
99.4 M | $ 10.83 | 4.74 % | $ 224 M | USA |
 |
Merit Medical Systems
MMSI
|
2.69 B | $ 67.65 | -1.36 % | $ 4 B | USA |
 |
Pulse Biosciences
PLSE
|
94.5 M | $ 22.81 | -0.91 % | $ 1.54 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
5.43 B | $ 11.9 | -0.13 % | $ 2.37 B | USA |
 |
Retractable Technologies
RVP
|
143 M | $ 0.64 | -2.05 % | $ 19.2 M | USA |
 |
LeMaitre Vascular
LMAT
|
616 M | $ 115.76 | 2.04 % | $ 2.62 B | USA |
 |
Predictive Oncology
POAI
|
52.9 M | - | - | $ 31.1 M | USA |
 |
STAAR Surgical Company
STAA
|
452 M | $ 26.3 | 2.45 % | $ 1.3 B | USA |
 |
BioLife Solutions
BLFS
|
399 M | $ 21.55 | 0.78 % | $ 993 M | USA |
 |
Stereotaxis
STXS
|
52.3 M | $ 1.94 | 0.52 % | $ 176 M | USA |
 |
Baxter International
BAX
|
20.1 B | $ 18.33 | 0.91 % | $ 9.4 B | USA |
 |
ResMed
RMD
|
5.1 B | $ 221.76 | 0.87 % | $ 32.4 B | USA |
 |
AtriCure
ATRC
|
654 M | $ 29.41 | 0.43 % | $ 1.4 B | USA |
 |
Harvard Bioscience
HBIO
|
80.1 M | $ 6.69 | -2.48 % | $ 297 M | USA |
 |
NeuroMetrix
NURO
|
15.3 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
280 M | $ 11.14 | 0.36 % | $ 455 M | USA |
 |
Becton, Dickinson and Company
BDX
|
55.3 B | $ 151.85 | -0.18 % | $ 43.7 B | USA |
 |
Nephros
NEPH
|
11.9 M | $ 3.01 | 4.88 % | $ 31.3 M | USA |
 |
OraSure Technologies
OSUR
|
403 M | $ 2.99 | -0.5 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
2.83 B | $ 118.32 | 0.61 % | $ 6.59 M | USA |